LXR inflammation
The collaboration with Wyeth LCC (a wholly-owned subsidiary of Pfizer Inc.) was initiated in 2001 and focuses on the development of new drugs for the treatment of inflammatory diseases with the liver X receptor (LXR) as a target protein. From September 2009, Wyeth took on full responsibility for research and development.
